- Rodman & Renshaw 16th Annual Global Investment Presentation on September 9, 2014 -
- Aegis Capital 2014 Healthcare and Technology Presentation on September 12, 2014 -
DURHAM, N.C., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference being held September 8 - 10, 2014 at the New York Palace Hotel in New York and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore at Wynn in Las Vegas.
| Event: | Rodman & Renshaw 16th Annual Global Investment Conference |
| Date: | Tuesday, September 9, 2014 |
| Time: | 10:00 a.m. Eastern Time |
| Location: | New York Palace Hotel, New York, NY |
| Event: | Aegis Capital Healthcare and Technology Conference |
| Date: | Friday, September 12, 2014 |
| Time: | 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) |
| Location: | Encore at Wynn, Las Vegas, NV |
Live audio webcasts of both the Rodman & Renshaw presentation and the Aegis Capital presentation will be available on the Company's website (www.heatbio.com) on the Investor Relations Events page at http://ir.heatbio.com/events. The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat's Viagenpumatucel-L (HS-110) will be entering Phase 2 trials against non-small cell lung cancer and its Vesigenurtacel-L (HS-410) is being evaluated in an ongoing Phase 1/2 clinical trial against bladder cancer.